Prospective, non-randomized, multi-center study assessing the long term safety and efficacy of the self expandable sirolimus eluting Xposition S stent in the treatment of unprotected left main coronary artery disease.

In the treatment of unprotected left main coronary artery (ULMCA) disease, previous mono-center studies have shown promising results with the previous generation of the self-expandable STENTYS stent (paclitaxel eluting stent, delivered via withdrawal of a sheath).

The TRUNC study aims at assessing at large scale the Xposition S in the treatment of ULMCA disease. The Xposition S is a sirolimus eluting stent, mounted on a balloon delivery system. The study aims at collecting clinical practice routine data from 200 patients.

Main Inclusion Criteria:

• Subject ≥ 18 years old;
• Presence of coronary artery stenosis in the unprotected Left Main (LM) Coronary Artery which is indicated for PCI and Xposition S stent treatment
• Left Main Coronary Artery reference vessel diameter ranging from 2.5 mm to 6.0 mm;
• The subject is able to provide voluntary informed consent, willing to comply with all study requirements and sign the written informed consent.

Main Exclusion Criteria:

• Recent STEMI (<1 month) ;
• SYNTAX score ≥ 33 ;
• Highly calcified lesions or excessive tortuosity at target lesion site;
• Subject unable to comply with dual antiplatelet therapy as recommended per guidelines;
• Planned cardiac surgery or valve intervention within the next 12 months.
• Participation to other investigational drug or device studies that have not reached their primary endpoint.

Patients with coronary artery stenosis (unprotected left main coronary artery), indicated for Percutaneous Coronary Intervention (PCI) and Xposition S stent treatment.